Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: FK 021; FR 71021

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fujisawa
  • Developer Astellas Pharma; Fujisawa
  • Class Antiallergics; Antiasthmatics; Antiulcers; Cytoprotectives; Quinolizines; Small molecules; Tetrazoles
  • Mechanism of Action Cell membrane modulators; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Irritable bowel syndrome
  • Discontinued Asthma; Peptic ulcer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in Japan (PO)
  • 30 Nov 2009 Preclinical trials in Irritable bowel syndrome in Japan (PO)
  • 25 Nov 2009 Pharmacodynamics data from preclinical studies in Irritable bowel syndrome presented at the GASTRO-2009 Joint Meeting (GASTRO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top